ZF2001: Perbedaan antara revisi

'''ZF2001''', bernama dagang '''RBDZIFIFAX''' atau '''ZF-DimerUZ-VAC-2001''', adalah sebuah [[vaksin COVID-19]] [[vaksin subunit|subunit protein]] yang dikembangkan oleh Anhui Zhifei Longcom dalam kolaborasi dengan Institut Mikrobiologi di [[Akademi Sains Tiongkok]].<ref name=":0">{{Cite web|title=Anhui Zhifei Longcom: RBD-Dimer – COVID19 Vaccine Tracker|url=https://covid19.trackvaccines.org/vaccines/27/|access-date=2020-12-27|website=covid19.trackvaccines.org}}</ref><ref>{{Cite web|title=COVID-19 Vaccine: RBD-Dimer by Anhui Zhifei Longcom Biopharma, Institute of Microbiology Chinese Academy of Sciences|url=https://covidvax.org/covid19-vaccine/AnhuiZhifei/Adjuvanted-recombinant-protein-Anhui-Zhifei-Longcom-Biopharma-Institute-of-Microbiology-Chinese-Acad|access-date=2020-12-27|website=covidvax.org|language=en}}</ref> Pada Desember 2020, kandidat vaksin tersebut menjalani pengujian tahap III dengan 29.000 partisipan di [[Tiongkok]], [[Ekuador]], [[Indonesia]], [[Malaysia]], [[Pakistan]], dan [[Uzbekistan]].<ref>{{Cite web|date=2020-11-20|title=Fifth Chinese Covid-19 vaccine candidate ready to enter phase 3 trials|url=https://www.scmp.com/news/china/science/article/3110690/coronavirus-chinas-cnbg-set-review-covid-19-vaccine-phase-3|access-date=2020-12-27|website=South China Morning Post|language=en}}</ref><ref name=":4" /> Jika pengujian tersebut berhasil, perusahaan tersebut berrencana untuk membuat 300 juta dosis vaksin setiap tahun.<ref name=":2" />